The era of easily analyzing body composition and health care for dogs like humans opens.Pawzmedi, a .. – MK

The era of easily analyzing body composition and health care for dogs like humans opens.

Pawzmedi, a pet healthcare start-up, announced on the 24th that a body composition analysis device for small animals based on bioimpedance technology has completed the official distribution process in Korea after obtaining final approval for KC certification.

This device is an optimization of bioimpedance technology for small animals that non-invasive measurement of biological signals. It is a similar principle to the ‘in-body’ commonly used during medical check-ups. This time, an algorithmic analysis device based on measurement data for small animals will be commercialized for the first time. In the future, technology and industrial value are expected in that it can be a data platform that can increase analysis precision through deep learning. The post-treatment focused pet medical environment could be a turning point in the transition to data-driven proactive prevention and customized health care systems. This is because it is possible to manage the health status of pets more systematically and scientifically before the disease occurs through regular body composition measurement and interpretation.

FuzzMedi has also signed a sales contract with UTB, one of the largest distributors of animal hospitals in Korea, to commercialize its products. Initially, it plans to expand distribution by focusing on the use of clinical bases specialized in small dog treatment environments.

It has already laid the groundwork for entering the global market. FuzzMedi verified technical stability and field applicability through more than 300 clinical environment PoCs (technical demonstration) centered on the Japanese market. It plans to officially launch it in the Korean and Japanese markets at the same time in the first half of next year.

Currently, FuzzMedi is undergoing the process of registering animal medical devices in Korea. As soon as the administrative process is completed, it plans to expand the service based on formal medical devices and expand its scope beyond simple measurement equipment to data analysis services that cover the entire life cycle of companion animals.

The approval of KC certification is meaningful in that it has laid an official foundation for supplying products to the actual market beyond the technology verification stage, said Oh Je-woo, CEO of FuzzMedi. “Based on the precise data accumulated through animal hospitals, we will present more advanced health care standards in the pet healthcare market.”